GemfibrozilThird Party Manufacturing in India

Gemfibrozil works by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear receptor that regulates lipid metabolism. Upon activation, PPAR-alpha increases the expression of lipoprotein lipase, an enzyme that breaks down triglycerides in circulating lipoproteins. Simultaneously, gemfibrozil reduces hepatic production of apolipoprotein C-III, which further enhances the clearance of triglyceride-rich particles from the blood.

This dual mechanism leads to significant reductions in serum triglyceride levels and very-low-density lipoprotein cholesterol (VLDL-C). Gemfibrozil also raises high-density lipoprotein cholesterol (HDL-C) levels by stimulating the production of apolipoproteins A-I and A-II. The overall effect is a shift toward a less atherogenic lipid profile, with decreased triglycerides, moderately reduced LDL cholesterol, and increased HDL cholesterol. Unlike statins which primarily target LDL cholesterol through HMG-CoA reductase inhibition, gemfibrozil is particularly effective for patients with hypertriglyceridemia and low HDL levels.

Therapeutic Uses

Gemfibrozil is prescribed for the management of lipid disorders:

• Hypertriglyceridemia (Type IV Hyperlipidemia): Primary indication for patients with severely elevated triglyceride levels at risk of pancreatitis
• Combined Hyperlipidemia (Type IIb): For patients with elevated triglycerides and LDL cholesterol who have not responded to diet and exercise
• Type V Hyperlipidemia: Used when chylomicronemia is present with elevated VLDL
• Low HDL Cholesterol: Helps raise HDL levels in patients with dyslipidemia

Why Manufacturers Choose Gemfibrozil

Gemfibrozil third party manufacturing in India is well-established, with numerous WHO-GMP certified facilities producing 600mg tablets. The molecule has been a mainstay of lipid management for decades and continues to see steady demand from both the domestic Indian market and export territories across Asia, Africa, and the Middle East. Indian manufacturers benefit from well-established supply chains for the raw material and cost-effective production processes.

The molecule is typically formulated as 600mg tablets and is available in both branded generic and PCD franchise models. For contract manufacturers, gemfibrozil offers the advantage of straightforward tablet compression with established formulation parameters, making it an efficient addition to any oral solid dosage manufacturing line.